Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014 - 16/07/18
, Ruzica Z. Conic, MD a, Cheryl L. Thompson, PhD b, Meg R. Gerstenblith, MD a, Jeremy S. Bordeaux, MD, MPH aAbstract |
Background |
Melanoma of unknown primary (MUP) is incompletely described on a population level.
Objective |
We sought to characterize stage IV MUP in a population-based cancer registry.
Methods |
We developed a novel search algorithm to identify cases of stage IV MUP in the Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. Cases of stage IV melanoma of known primary (MKP) served as a comparison group. Age-standardized incidence rates, demographic characteristics, adjusted disease-specific survival, and Cox proportional hazard models were calculated for MUP and MKP.
Results |
A total of 322 stage IV MUP cases and 12,796 stage IV MKP cases were identified in Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. The incidence of stage IV MUP is increasing, particularly for patients younger than 30 years of age. In multivariate analyses, age older than 50 and a lack of surgical treatment were negative prognostic factors for stage IV MUP. Relative survival, but not 5-year adjusted disease-specific survival, was higher for stage IV MUP than for MKP.
Limitations |
Limitations include the retrospective study design and possible misclassification of MUP.
Conclusions |
The incidence of stage IV MUP is increasing, and stage IV MUP shares similar prognostic factors with stage IV MKP, including age and surgical treatment.
Le texte complet de cet article est disponible en PDF.Key words : melanoma of unknown primary, Surveillance, Epidemiology, and End Results 18
Abbreviations used : CI, HR, DSS, MUP, MKP, NOS, SEER
Plan
| Supported by the Char and Chuck Fowler Family Foundation. Dr Conic is funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award No. 5 T32 AR 7569-23. |
|
| Conflicts of interest: None disclosed. |
|
| The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Portions of this work were presented as a poster at the American Society for Dermatologic Surgery 2016 Annual Meeting, New Orleans, LA; November 10-13, 2016. |
|
| Reprints not available from the authors. |
Vol 79 - N° 2
P. 258 - août 2018 Retour au numéro
Article précédent
- Red meat and processed meat intake and risk for cutaneous melanoma in white women and men: Two prospective cohort studies
- Hsi Yen, Wen-Qing Li, Ashar Dhana, Tricia Li, Abrar Qureshi, Eunyoung Cho
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
- Mark Lebwohl, Andrew Blauvelt, Carle Paul, Howard Sofen, Jolanta W?g?owska, Vincent Piguet, Daniel Burge, Robert Rolleri, Janice Drew, Luke Peterson, Matthias Augustin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?